Follow
Zoran Culig
Zoran Culig
Professor of Experimental Urology, Medical University of Innsbruck
Verified email at i-med.ac.at - Homepage
Title
Cited by
Cited by
Year
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
Z Culig, A Hobisch, MV Cronauer, C Radmayr, J Trapman, A Hittmair, ...
Cancer research 54 (20), 5474-5478, 1994
13351994
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.
Z Culig, A Hobisch, MV Cronauer, AC Cato, A Hittmair, C Radmayr, ...
Molecular endocrinology 7 (12), 1541-1550, 1993
6081993
Prevention and early detection of prostate cancer
J Cuzick, MA Thorat, G Andriole, OW Brawley, PH Brown, Z Culig, ...
The lancet oncology 15 (11), e484-e492, 2014
5872014
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor
A Hobisch, IE Eder, T Putz, W Horninger, G Bartsch, H Klocker, Z Culig
Cancer research 58 (20), 4640-4645, 1998
5651998
Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
Z Culig, J Hoffmann, M Erdel, IE Eder, A Hobisch, A Hittmair, G Bartsch, ...
British journal of cancer 81 (2), 242-251, 1999
4881999
Regulation of prostatic growth and function by peptide growth factors
Z Culig, A Hobisch, MV Cronauer, C Radmayr, A Hittmair, J Zhang, ...
The Prostate 28 (6), 392-405, 1996
4011996
Distant metastases from prostatic carcinoma express androgen receptor protein
A Hobisch, Z Culig, C Radmayr, G Bartsch, H Klocker, A Hittmair
Cancer research 55 (14), 3068-3072, 1995
3871995
Interleukin-6 and prostate cancer progression
PC Smith, A Hobisch, DL Lin, Z Culig, ET Keller
Cytokine & growth factor reviews 12 (1), 33-40, 2001
3812001
Interleukin‐6 regulation of prostate cancer cell growth
Z Culig, H Steiner, G Bartsch, A Hobisch
Journal of cellular biochemistry 95 (3), 497-505, 2005
3712005
Androgen receptor signaling in prostate cancer
Z Culig, FR Santer
Cancer and Metastasis Reviews 33, 413-427, 2014
2922014
The mutational landscape of prostate cancer
CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ...
European urology 64 (4), 567-576, 2013
2862013
Androgen receptors in prostate cancer.
Z Culig, H Klocker, G Bartsch, A Hobisch
Endocrine-related cancer 9 (3), 155-170, 2002
2832002
Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review
S Madersbacher, N Sampson, Z Culig
Gerontology 65 (5), 458-464, 2019
2682019
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205
M Puhr, J Hoefer, G Schäfer, HHH Erb, SJ Oh, H Klocker, I Heidegger, ...
The American journal of pathology 181 (6), 2188-2201, 2012
2682012
Alternative mechanisms of miR-34a regulation in cancer
E Slabáková, Z Culig, J Remšík, K Souček
Cell death & disease 8 (10), e3100-e3100, 2017
2442017
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines
FR Santer, PPS Höschele, SJ Oh, HHH Erb, J Bouchal, IT Cavarretta, ...
Molecular cancer therapeutics 10 (9), 1644-1655, 2011
2342011
JAK-STAT signaling in cancer: From cytokines to non-coding genome
J Pencik, HTT Pham, J Schmoellerl, T Javaheri, M Schlederer, Z Culig, ...
Cytokine 87, 26-36, 2016
2302016
Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue
A Hobisch, H Rogatsch, A Hittmair, D Fuchs, G Bartsch Jr, H Klocker, ...
The Journal of pathology 191 (3), 239-244, 2000
2242000
ZEB 1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
S Meidhof, S Brabletz, W Lehmann, BT Preca, K Mock, M Ruh, J Schüler, ...
EMBO molecular medicine 7 (6), 831-847, 2015
2232015
Adipose tissue–derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth
IT Cavarretta, V Altanerova, M Matuskova, L Kucerova, Z Culig, C Altaner
Molecular Therapy 18 (1), 223-231, 2010
2212010
The system can't perform the operation now. Try again later.
Articles 1–20